Skip to main content

Table 2 The causes of failure to complete adjuvant chemotherapy

From: Therapeutic efficacy of dose-reduced adjuvant chemotherapy with S-1 in patients with pancreatic cancer: a retrospective study

 

High TDR

(n = 24)

Low TDR

(n = 16)

P value

Recurrence

10 (42%)

5 (31%)

0.504

Adverse event (CTCAE Grade 3 or 4)

4 (16%)

10 (63%)

0.003

 -Nausea

0(0%)

3 (30%)

 

 -Diarrhea

1 (25%)

0 (0%)

 

 -Heart failure

1 (25%)

0 (0%)

 

 -Interstitial pneumonia

0 (0%)

1 (10%)

 

 -Liver dysfunction

0 (0%)

2 (20%)

 

 -Others

2 (50%)

4 (40%)

 

Death

1 (5%)

0 (0%)

0.408

Othersa

9 (38%)

1 (6%)

0.013

  1. TDI Total dose intensity, CTCAE Common Terminology Criteria for Adverse Events
  2. aLow-performance status or the patient’s decision to not continue treatment were included